A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

The Make America Healthy Again Commission is supposed to promote health coverage options that support helpful lifestyle ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...

Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult and pediatric patients.